Clinical Trial Update: Open-label Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy [Phase 4]

View source ↗

Summary

An open-label Phase 4 study from Amryt Pharma is evaluating metreleptin in patients with partial lipodystrophy, and recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Partial Lipodystrophy

Drugs mentioned

• MYALEPT (METRELEPTIN)

Snippet

Sponsor: Amryt Pharma | Conditions: Partial Lipodystrophy | Phase 4 | Status: RECRUITING